Roche Presents Results of Evrysdi (risdiplam) in RAINBOWFISH Study for the Treatment of Neuromuscular Disorder at WMS 2021
Shots:
- The RAINBOWFISH study evaluates the efficacy and safety of Evrysdi in babies aged birth to 6wks. with pre-symptomatic SMA
- The results showed that 4 out of 5 patients treated with Evrysdi for 12 mos. were able to stand & walk independently within the WHO windows for healthy children. Additionally- all five infants maintained the ability to swallow and were able to feed exclusively orally after 12mos. of treatment
- The results further support the continued clinical investigation of SRP-9001 in DMD. Additionally- the company also presents the data from the SRP-9001- 101/002/003 studies evaluating the efficacy- safety- and durability of SRP-9001 for DMD
Ref: Roche | Image: Roche
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com